SCHEMBL2283107

SCHEMBL2283107

COC(=O)COc1cccc(C=CC(=O)c2c(OCC(=O)OC)cc(C)n(C)c2=O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYSLTR2 Q9NS75 3/20 0.46
CYSLTR1 Q9Y271 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.44
ABCG2 Q9UNQ0 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
CYP1A1 P04798 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
NFKB1 P19838 1/20 0.42
RAB9A P51151 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
CYP1B1 Q16678 1/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAOB P27338 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2283102 1.00 CYSLTR2 (0.46) CYSLTR2CYSLTR1L3MBTL1ABCG2SMN1; SMN2
SCHEMBL2277984 0.95 ABCG2 (0.49) CYSLTR2CYSLTR1L3MBTL1ABCG2SMN1; SMN2
SCHEMBL2277980 0.95 ABCG2 (0.49) CYSLTR2CYSLTR1L3MBTL1ABCG2SMN1; SMN2
SCHEMBL2274827 0.93 CYSLTR2 (0.42) CYSLTR2CYSLTR1L3MBTL1ABCG2SMN1; SMN2
SCHEMBL2274821 0.93 CYSLTR2 (0.42) CYSLTR2CYSLTR1L3MBTL1ABCG2SMN1; SMN2
SCHEMBL2280010 0.92 CYSLTR2 (0.41) CYSLTR2CYSLTR1L3MBTL1ABCG2SMN1; SMN2
SCHEMBL2283693 0.92 ALDH1A1 (0.47) CYSLTR2CYSLTR1L3MBTL1ABCG2SMN1; SMN2
SCHEMBL2282703 0.92 ALDH1A1 (0.48) CYSLTR2CYSLTR1L3MBTL1ABCG2SMN1; SMN2
SCHEMBL2282707 0.92 ALDH1A1 (0.48) CYSLTR2CYSLTR1L3MBTL1ABCG2SMN1; SMN2
SCHEMBL2283697 0.92 ALDH1A1 (0.47) CYSLTR2CYSLTR1L3MBTL1ABCG2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 CYSLTR2 829/4885CYSLTR1 466/4885L3MBTL1 1837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.